ONO-2416

ONO-2416 is an investigational small molecule drug developed by Ono Pharmaceutical. It has been evaluated in Phase I clinical trials in Japan, specifically in healthy adult male subjects, to assess its safety, tolerability, and pharmacokinetics. The clinical development program included assessments of single and multiple oral doses, mass balance studies, and electroencephalography (EEG) to monitor potential central nervous system effects. While the specific biological target has not been widely disclosed in public pipeline summaries, the inclusion of EEG assessments suggests a potential application in neurological or psychiatric disorders.